On Nov 14, major Wall Street analysts update their ratings for $Progyny (PGNY.US)$, with price targets ranging from $17 to $22.
BofA Securities analyst Allen Lutz maintains with a buy rating, and maintains the target price at $21.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $30 to $17.
Jefferies analyst Glen Santangelo maintains with a buy rating, and adjusts the target price from $24 to $19.
Cantor Fitzgerald analyst Sarah James maintains with a buy rating, and adjusts the target price from $25 to $22.
Furthermore, according to the comprehensive report, the opinions of $Progyny (PGNY.US)$'s main analysts recently are as follows:
Progyny's stock experienced an 11% decline following the earnings announcement. This was a result of better-than-anticipated selling season outcomes being eclipsed by repeated reductions concerning atypical usage, which has raised concerns regarding forecasting models. While there is an anticipation for evidence of accurate forecasting, there is also an acknowledgment of the need for a more cautious outlook on the company's guidance.
Q3 results indicate continuing pressure due to an unfavorable utilization mix, and there's limited visibility on when these conditions might shift. Despite the uncertainty caused by utilization trends, there remains a positive outlook on the fertility end-market and Progyny's dominant market position.
The firm is revising its projections to account for the outcomes of the selling season. This includes the addition of 1.1 million members, which is somewhat offset by approximately 700,000 due to a previously disclosed client departure. Additionally, the firm is adopting a more cautious stance on the expected utilization and composition for Q4 and the full year of FY25.
Here are the latest investment ratings and price targets for $Progyny (PGNY.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月14日，多家华尔街大行更新了$Progyny (PGNY.US)$的评级，目标价介于17美元至22美元。
美银证券分析师Allen Lutz维持买入评级，维持目标价21美元。
巴克莱银行分析师Stephanie Davis维持买入评级，并将目标价从30美元下调至17美元。
富瑞集团分析师Glen Santangelo维持买入评级，并将目标价从24美元下调至19美元。
坎托·菲茨杰拉德分析师Sarah James维持买入评级，并将目标价从25美元下调至22美元。
此外，综合报道，$Progyny (PGNY.US)$近期主要分析师观点如下：
Progyny的股票在财报公布后经历了11%的下跌。这是由于超出预期的销售季节结果被关于非典型使用的重复修正所掩盖，这引发了对预测模型的担忧。虽然期待有准确预测的证据，但也承认需要对公司的指导持更加谨慎的态度。
Q3的结果表明由于不利的利用组合，压力持续，并且对这些情况何时可能发生变化的可见性有限。尽管由于利用趋势带来的不确定性，但对生育终端市场和Progyny强大的市场地位依然持乐观态度。
公司正在调整其预测，以考虑销售季节的结果。这包括新增110万成员，但由于之前披露的客户离开，约70万成员的增加有所抵消。此外，公司对第四季度及2025财年的预期利用率和构成持更加谨慎的态度。
以下为今日4位分析师对$Progyny (PGNY.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
